Key Segmentation
By Service Type
-
Adeno-Associated Virus (AAV) Vector Manufacturing
-
Lentiviral Vector Manufacturing
-
Plasmid DNA Manufacturing
-
Cell Line Development and Production
By Therapeutic Area
-
Neurology
-
Oncology
-
Ophthalmology
-
Cardiovascular
-
Other Therapeutic Areas
By Vector Type
-
Self-complementary AAV (scAAV)
-
Single-stranded AAV (ssAAV)
-
Hybrid AAV (HAAV)
-
Other Vector Types
By Capacity
-
Small-scale
-
Medium-scale
-
Large-scale
By End User
-
Large Pharma
-
Biotech Start-ups
-
Academic & Non-Profit Institutes
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The major growth factors include rising demand for gene therapy manufacturing services, increasing outsourcing to specialized CDMOs, expanding clinical pipelines, scalable AAV manufacturing advancements, regulatory approvals, and growing prevalence of rare genetic disorders.
The adeno-associated virus (AAV) vector manufacturing dominated the market in 2025 due to rising gene therapy demand and increasing outsourcing to specialized CDMOs.
North America dominated the adeno-associated virus (AAV) CDMO market in 2025 due to advanced biotechnology infrastructure, strong biopharmaceutical presence, and increasing gene therapy investments.